Differential Adverse Events Between TNF-α Inhibitors and IL-17 Axis Inhibitors for the Treatment of Spondyloarthritis-Reference-Cited by-同舟云学术

Differential Adverse Events Between TNF-α Inhibitors and IL-17 Axis Inhibitors for the Treatment of Spondyloarthritis

Published:2015-04-19 Issue:2 Volume:1 Page:239-254
ISSN:2198-6002
Container-title:Current Treatment Options in Rheumatology
language:en
Short-container-title:Curr Treat Options in Rheum

Author:

Antonelli Maria,Khan Muhammad A.,Magrey Marina N.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40674-015-0022-7.pdf

Reference67 articles.

1. Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002;136(12):896–907.

2. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14–7.

3. Davis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. Semin Arthritis Rheum. 2008;38(2):83–100.

4. Semble AL, Davis SA, Feldman SR. Safety and tolerability of tumor necrosis factor-a inhibitors in psoriasis: a narrative review. Am J Clin Dermatol. 2014;15:37–43. This very thorough narrative review discusses safety and tolerability of TNF-inhibitors in the treatment of moderate-to-severe plaque psoriasis.

5. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149–60.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of severe ankylosing spondylitis with high-dose secukinumab: A retrospective study;2022-09-23

2. A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report;Current Drug Safety;2020-02-03

3. Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors;JAMA Network Open;2019-10-18

4. Secukinumab: A Review in Ankylosing Spondylitis;Drugs;2019-02-22

5. A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis;JCR: Journal of Clinical Rheumatology;2018-01